The Ursula dividend is a shot in the arm for the UK vaccine industry –

The result? There will be lots of demand for more green, renewable energy, and plenty of Treasury cash, and guaranteed long-term contracts, to help make that happen.

Likewise, Britain will want to reduce the amount of trade that is routed through Rotterdam, and relocate it to British ports.

It is already clear that rigid enforcement of the paperwork means it is now virtually impossible to sell food to the EU, so instead UK consumption of domestic produce will rise.

And at the same time, as we will not want to rely on European imports, there will be room for technology such as vertical farms that allow hot-weather vegetables and fruit to be grown closer to home. The City will have to switch to designing financial products for a world market as it gets frozen out of European ones.

The list goes on and on. In each case, markets will open up as government and private companies work out they can’t rely on Europe for supplies, or should at least have emergency back-ups in place. The EU is turning increasingly aggressive towards its neighbours.

In a crisis, as with vaccines, it will lash out, and impose export controls. That, of course, is up to them. But it creates a huge potential space for British companies. The UK will be far more self-reliant going forward, and far more plugged into trading with Africa, the Pacific and the Americas. Whether that is an improvement in the medium-term is open to question.

In truth, both the EU and the UK would be better off with completely free trade, mutual recognition of each other’s standards, and co-operation when problems emerge. But that isn’t going to happen anytime soon.

In the meantime British companies should take the “Ursula dividend” and run, seizing the chance to create alternatives, and building new industries in the process.

And the people with new jobs making vaccines in Stockton and Livingston should raise a glass to the blonde lady in Brussels – they wouldn’t have that work without her.